Issue of Equity

In brief · summary, not quotable

Coiled Therapeutics plc announced the issuance of 934,783 new ordinary shares, comprising 434,783 to a consultant and 500,000 to a vendor, to settle outstanding amounts. These new shares will rank pari passu with existing shares and are expected to be admitted to trading on AIM around June 3, 2026. Following admission, the company's total issued share capital will be 426,791,322 ordinary shares, each carrying one vote. This issuance will dilute existing shareholders' percentage ownership but is a non-cash transaction to settle liabilities.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the issue of 934,783 new ordinary shares of one pence each ("New Ordinary Shares") in settlement of amounts owing to a consultant (434,783 New Ordinary Shares) and a vendor (500,000 New Ordinary Shares). The issue of the New Ordinary Shares is conditional on Admission (defined below).

Admission and Total Voting Rights

Application will be made for the New Ordinary Shares to be admitted to trading on AIM, which is expected to occur on or around 3 June 2026 ("Admission"). The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares of one pence each ("Ordinary Shares") traded on AIM.

Following Admission, the Company's issued share capital will comprise 426,791,322 Ordinary Shares, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 426,791,322 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

About AO-252

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.